Core Viewpoint - B. Riley has raised the price target for Vanda Pharmaceuticals (VNDA) to $14 from $11, maintaining a Buy rating, following the FDA's approval of Nereus for motion sickness-induced vomiting prevention, indicating a positive outlook for the company as it is seen as an "ongoing turnaround story" [1] Summary by Category Company Performance - The FDA approval of Nereus is expected to unlock over $100 million in peak revenue for Vanda Pharmaceuticals [1] - The approval is also significant for the potential approval of tradipitant, which is related to GLP-1 induced nausea [1] Market Position - Vanda Pharmaceuticals is currently trading at an "excessive discount" as it approaches two more potential approvals within the next 12 months [1]

分组1 - Vanda Pharmaceuticals Inc. (VNDA) experienced a significant increase in stock price following the FDA's approval of Nereus for treating motion sickness [1] - The company is focused on developing innovative therapies, leveraging unique mechanisms of action and first-in-class treatments [1] - The analyst emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, and clinical trial design while balancing financial fundamentals [1] 分组2 - The biotech sector is characterized by the potential for breakthrough science to yield substantial returns, necessitating careful scrutiny of investment opportunities [1] - The analyst aims to provide insights that help investors understand both the opportunities and risks inherent in the biotech industry [1]

Core Viewpoint - Vanda Pharmaceuticals (VNDA.US) stock price increased by over 25.46% following the FDA approval of its new drug Nereus, which is intended for the prevention of vomiting induced by motion [1][2]. Group 1: FDA Approval and Drug Details - The FDA approval of Nereus is based on results from three clinical studies that compared the drug group with a placebo group to assess the occurrence of vomiting [2]. - Data from the trials indicated that Nereus achieved a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios [2]. Group 2: Market Implications - The approval of Nereus is expected to provide a new commercialization growth point for the company and further enrich its product portfolio in the central nervous system and related indications [2].

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index falling over 100 points, down 0.28% to 48,229.87, NASDAQ slipping 0.26% to 23,359.33, and S&P 500 dropping 0.26% to 6,878.07 [1] - European shares also fell, with the eurozone's STOXX 600 down 0.14%, Spain's IBEX 35 Index down 0.27%, London's FTSE 100 down 0.09%, and France's CAC 40 down 0.23% [6] - Asian markets closed mixed, with Hong Kong's Hang Seng Index down 0.87%, China's Shanghai Composite up 0.09%, and India's BSE Sensex up 0.64% [7] Commodities - In commodity trading, oil increased by 0.1% to $58.02, while gold decreased by 0.8% to $4,351.00. Silver fell 7.3% to $72.255, and copper dropped 1.9% to $5.6710 [5] Company News - Anghami Inc. shares surged 50% to $3.7306 following a year-over-year increase in H1 results [9] - Vanda Pharmaceuticals Inc. saw a 32% increase in shares to $9.28 after receiving FDA approval for NEREUS [9] - Intelligent Bio Solutions Inc. shares rose 102% to $8.27 due to a strategic manufacturing partnership with Syrma Johari MedTech [9] - Corcept Therapeutics Incorporated shares plummeted 52% to $34.04 after receiving a Complete Response Letter from the FDA [9] - FuelCell Energy, Inc. shares fell 10% to $7.18 after filing for an amended common stock offering [9] - SMX Public Limited Company shares dropped 37% to $32.30 [9] Economic Indicators - U.S. initial jobless claims decreased by 16,000 to 199,000, better than market estimates of 220,000 [10] - U.S. crude oil inventories, excluding the Strategic Petroleum Reserve, fell by 1.934 million barrels, marking the largest weekly decline since mid-November, compared to market estimates of a 0.9 million-barrel decrease [10][2]

Core Viewpoint - The FDA's approval of Vanda's drug Nereus marks a significant advancement in preventing motion-induced vomiting, which may also provide a new treatment avenue for nausea associated with GLP-1 weight-loss medications [1] Group 1 - Vanda's drug Nereus is specifically designed to prevent motion-induced vomiting [1] - The approval by the FDA opens potential opportunities for the drug to be used in treating nausea linked to GLP-1 weight-loss drugs [1]

Core Viewpoint - Vanda Pharmaceuticals (VNDA.US) shares surged over 32% to $9.33 following FDA approval of its new drug Nereus, aimed at preventing exercise-induced vomiting [1] Group 1: FDA Approval and Drug Details - The FDA's approval of Nereus is based on results from three clinical studies comparing the drug to a placebo in terms of vomiting occurrence [1] - Data indicates that Nereus achieved a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios [1] Group 2: Market Implications - The approval of Nereus is expected to provide a new commercial growth opportunity for the company and enhance its product portfolio in the central nervous system and related indications [1]

Core Viewpoint - Vanda Pharmaceuticals (VNDA.US) shares surged over 32% to $9.33 following FDA approval of its new drug Nereus, aimed at preventing exercise-induced vomiting [1] Group 1: FDA Approval and Drug Details - The FDA approval of Nereus is based on results from three clinical studies comparing the drug group to a placebo group to assess vomiting occurrences [1] - Data indicates that Nereus achieved a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios [1] Group 2: Market Implications - The approval is expected to provide a new commercialization growth point for the company and enhance its product portfolio in the central nervous system and related indications [1]

Market Overview - The U.S. stock market is concluding a strong year with major indices showing impressive annual growth, driven by resilient corporate earnings and enthusiasm for artificial intelligence [1][2] - The S&P 500 is on track for an annual gain exceeding 17%, while the Nasdaq Composite has surged approximately 21% for the year, largely due to strong performance in the AI sector [2][3] - The Dow Jones Industrial Average is set to close the year with a gain of around 13.7% [3] Commodity Market - Commodity markets have shown notable activity, with gold rising 1.4%, copper gaining 4.4%, and silver posting a significant jump of 10.9% [4] Corporate Developments - Nvidia has seen its stock surge around 180% this year due to strong demand for its new H200 AI chips, with the company seeking to ramp up production [9] - Other tech sector performers include Western Digital with a 260% gain, Seagate Technology up 210%, and Micron Technology rising 178% [9] - Vanda Pharmaceuticals' shares rose significantly after FDA approval of its motion sickness drug, marking a milestone for the company [10] - Ferrexpo faces ongoing challenges due to the conflict in Ukraine and liquidity issues, despite strong global mining markets [11] - Wealth manager Walker Crips reported widening first-half losses ahead of its takeover by PhillipCapital [11] - Major companies like Apple, Microsoft, Tesla, and Alphabet continue to be closely monitored, with Apple showing a slight gain of 0.13% and Tesla down 3.27% [12] Future Outlook - The market remains poised for continued innovation and growth, particularly in AI and technological advancements, as investors look ahead to upcoming economic data and corporate earnings in 2026 [13]

Core Viewpoint - Vanda Pharmaceuticals' stock surged over 26% to $8.9 following the FDA approval of its drug for preventing exercise-induced nausea, marking the first such approval in over 40 years [1] Company Summary - Vanda Pharmaceuticals announced the FDA approval of its drug named Nereus, which is designed to prevent exercise-induced vomiting [1] - The company plans to launch Nereus in the coming months [1] Industry Summary - The approval of Nereus represents a significant milestone in the pharmaceutical industry, as it is the first drug of its kind approved in over four decades [1]

Key Takeaways VNDA won FDA approval for tradipitant, branded Nereus, to prevent vomiting caused by motion sickness.Vanda Pharmaceuticals said Nereus is the first new motion sickness drug in more than 40 years.VNDA shares surged 18% after hours following the approval, extending gains into pre-market trading.Vanda Pharmaceuticals, Inc. (VNDA) announced that the FDA has approved its candidate tradipitant for the prevention of vomiting induced by motion.The drug has been approved under the brand name Nereus.Tra ...